ATE433753T1 - Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe - Google Patents

Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe

Info

Publication number
ATE433753T1
ATE433753T1 AT98907211T AT98907211T ATE433753T1 AT E433753 T1 ATE433753 T1 AT E433753T1 AT 98907211 T AT98907211 T AT 98907211T AT 98907211 T AT98907211 T AT 98907211T AT E433753 T1 ATE433753 T1 AT E433753T1
Authority
AT
Austria
Prior art keywords
derivatives
composition
prostaglandin
delayed release
release prostaglandin
Prior art date
Application number
AT98907211T
Other languages
English (en)
Inventor
Michio Hara
Yasuhide Horiuchi
Fuminori Tamura
Keishi Yamasaki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE433753T1 publication Critical patent/ATE433753T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT98907211T 1997-03-14 1998-03-13 Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe ATE433753T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6150197 1997-03-14
PCT/JP1998/001057 WO1998041210A1 (en) 1997-03-14 1998-03-13 Sustained-release prostaglandin i derivative preparation

Publications (1)

Publication Number Publication Date
ATE433753T1 true ATE433753T1 (de) 2009-07-15

Family

ID=13172913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907211T ATE433753T1 (de) 1997-03-14 1998-03-13 Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe

Country Status (13)

Country Link
US (1) US6656502B1 (de)
EP (1) EP0947196B1 (de)
JP (1) JP3744941B2 (de)
CN (1) CN100502877C (de)
AT (1) ATE433753T1 (de)
AU (1) AU6310898A (de)
CA (1) CA2255052C (de)
DE (1) DE69840908D1 (de)
DK (1) DK0947196T3 (de)
ES (1) ES2328191T3 (de)
NO (1) NO985299L (de)
PT (1) PT947196E (de)
WO (1) WO1998041210A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092760A1 (en) * 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
AU2003296852A1 (en) * 2002-09-18 2004-05-04 Elan Corporation, Plc Multiparticulate modified release composition comprising beraprost
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
ATE341312T1 (de) * 2003-05-20 2006-10-15 Ethypharm Sa Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
WO2005007081A2 (en) 2003-05-22 2005-01-27 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
ES2451790T3 (es) * 2009-08-07 2014-03-28 Scipharm Sàrl Composición para el tratamiento de la fibrosis quística
WO2011099573A1 (ja) 2010-02-12 2011-08-18 大正製薬株式会社 徐放性製剤
CN106822013B (zh) * 2015-11-30 2020-05-12 北京泰德制药股份有限公司 前列环素类似物缓释制剂
CN107496348A (zh) * 2017-08-28 2017-12-22 天津昂赛细胞基因工程有限公司 一种用于组织损伤修复的水凝胶及制备方法
CA3082009A1 (en) 2017-11-16 2019-05-23 Nippon Shinyaku Co., Ltd. Controlled-release preparation
US12427145B2 (en) 2019-02-03 2025-09-30 Innovate Therapeutics Llc Controlled release pharmaceutical composition of Selexipag or it's active metabolite
CA3164676A1 (en) 2019-12-23 2021-07-01 Toray Industries, Inc. Drug for preventing dialysis shift or renal death
TW202317089A (zh) 2021-06-16 2023-05-01 日商東麗股份有限公司 罹患慢性腎臟病的貓的治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
JPH0759521B2 (ja) * 1985-09-30 1995-06-28 藤沢薬品工業株式会社 ゲル層形成型徐放性製剤
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
JPH02218621A (ja) * 1989-02-20 1990-08-31 Nippon Chemiphar Co Ltd 徐放性製剤
JPH02225416A (ja) * 1989-02-28 1990-09-07 Toray Ind Inc ５，６，７―トリノル―４，８―インタ―ｍ―フェニレンＰＧＩ↓２誘導体の経口用製剤
JP3007387B2 (ja) * 1990-07-16 2000-02-07 エーザイ株式会社 徐放性製剤用基剤粉末
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form

Also Published As

Publication number Publication date
JP3744941B2 (ja) 2006-02-15
ES2328191T3 (es) 2009-11-10
PT947196E (pt) 2009-09-24
AU6310898A (en) 1998-10-12
EP0947196B1 (de) 2009-06-17
CN100502877C (zh) 2009-06-24
CA2255052A1 (en) 1998-09-24
EP0947196A1 (de) 1999-10-06
NO985299L (no) 1999-01-14
EP0947196A4 (de) 2005-01-12
CA2255052C (en) 2009-09-15
DE69840908D1 (de) 2009-07-30
CN1219132A (zh) 1999-06-09
US6656502B1 (en) 2003-12-02
DK0947196T3 (da) 2009-10-12
NO985299D0 (no) 1998-11-13
WO1998041210A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
ATE433753T1 (de) Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe
NO890075D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazoler.
ATE223378T1 (de) Prolineamid-derivate
DE69732170D1 (de) Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan
ATE445597T1 (de) ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß
EP0668073A3 (de) Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe.
CA2382919A1 (en) Bicyclic imidazo-3-yl-amine derivatives
DK0519820T3 (da) Matrixtablet, som muliggør længerevarende frigivelse af indapamid efter oral administration
CA2344053A1 (en) Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
DK545889A (da) Anti-human-immundefektvirus-praeparat
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
NO905327L (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbamoylderivater.
PT806202E (pt) Composicao farmaceutica a base de matrizes lipofilas estabilizadas para a libertacao controlada de principios activos
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
CA2119777A1 (en) An Ameliorant for Blood Lipid Metabolism
DK0382533T3 (da) Indolderivater
DE3778165D1 (de)
ES2141134T3 (es) Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares.
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
BG105178A (bg) Нови 2,3,3а,4,9,9а-хексахидро-8-хидрокси-1н-бенз/f/индоли, метод за получаването им и приложението им като лекарствени средства
EP0509098A4 (en) Ataractic
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
NO890328D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 4-amino-2,3-disubstituert-6,7-dihydro-5h-1-pyrindinderivater.
NO891678D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0947196

Country of ref document: EP